-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Suzhou, October 21, 2021/PRNewswire/ - On October 21, 2021, Kaifeng Pharmaceutical Co.
GT90008 is a dual-target antibody against PD-L1 and TGF-βR2, which can simultaneously inhibit the high activity of PD-L1 and TGF-βR2, and has the potential to become a best-in-class drug
Dr.
About Kaixing Pharmaceutical
Founded in 2009, Kapport Pharmaceuticals focuses on the development and industrialization of potential "best-in-class" and "first-in-class" innovative drugs, and is committed to becoming a leader in the research, development and commercialization of innovative therapies
Source: Kaifeng Pharmaceutical